Marché mondial des inhibiteurs de la voie Hedgehog – Tendances et prévisions de l’industrie jusqu’en 2029

 Analyse et taille du marché

Ces dernières années, le marché des inhibiteurs de la voie Hedgehog devrait connaître une croissance rapide au cours de la période de prévision. Selon l'American Cancer Society (ACS), 5,4 millions de personnes dans le monde reçoivent un diagnostic de cancer de la peau épidermoïde et basocellulaire chaque année, 3,3 millions de personnes développant un cancer de la peau épidermoïde et plus de 80 % de la population développant un carcinome basocellulaire. L'augmentation des cas de cancer devrait influencer l'expansion du marché au cours de la période de prévision. Les inhibiteurs de la voie Hedgehog sont préférés aux traitements conventionnels contre le cancer en raison de la demande croissante de traitements indolores. Tous ces facteurs conduisent à la forte demande d'inhibiteurs de la voie Hedgehog dans le secteur de la santé.

Data Bridge Market Research analyse que le marché des inhibiteurs de la voie Hedgehog était évalué à 531,39 millions USD en 2021 et devrait atteindre 840,58 millions USD d'ici 2029, enregistrant un TCAC de 5,90 % au cours de la période de prévision de 2022 à 2029. Le rapport de marché organisé par l'équipe Data Bridge Market Research comprend une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Définition du marché

Les inhibiteurs de la voie Hedgehog sont de petites molécules qui appartiennent à une nouvelle famille de médicaments thérapeutiques qui ciblent principalement les protéines impliquées dans la régulation de la voie Hedgehog. Ces protéines sont une famille de protéines qui contrôlent la différenciation cellulaire et sont impliquées dans l'organogenèse, qui s'est avérée favoriser la prolifération des cellules souches chez les adultes. Une activation incorrecte des voies de signalisation Hedgehog peut entraîner la progression de cancers tels que ceux du poumon, de la prostate, du pancréas, du sein, du cerveau, de la peau et d'autres.

Portée du rapport et segmentation du marché

Hedgehog Pathway Inhibitors? Market Dynamics

Drivers

• Increasing prevalence of basal cell carcinoma and acute myeloid leukaemia

The rising prevalence of basal cell carcinoma and acute myeloid leukaemia is anticipated to influence the hedgehog pathway inhibitors? market's growth. Chronic infections, a history of skin cancer, exposure to specific chemicals, skin inflammations, smoking, and UV exposure are all risk factors for basal cell carcinoma and acute myeloid leukaemia. Basal cell carcinoma and acute myeloid leukaemia are more common as a result of these risk factors. Consequently, the hedgehog pathway inhibitors market is expected to rise throughout the forecast period.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of hedgehog pathway inhibitors? market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the hedgehog pathway inhibitors? market. Additionally, high disposable income and sedentary lifestyle of people will result in the expansion of hedgehog pathway inhibitors? market. Along with this, rising geriatric population and favourable reimbursement policies will enhance the growth rate of the market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the hedgehog pathway inhibitors? market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the hedgehog pathway inhibitors? market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the drug development and distribution? will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the hedgehog pathway inhibitors? market. Additionally, side effects of hedgehog pathway inhibitors? will act as market restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This hedgehog pathway inhibitors? market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hedgehog pathway inhibitors? market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Hedgehog pathway inhibitors? market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Hedgehog Pathway Inhibitors? Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. This can be ascribed to severe disruptions in their respective manufacturing and supply-chain operations therefore as consequence of multiple precautionary lockdowns and other limitations imposed by governments all over the world. The hedgehog pathway inhibitors market is no exception. Furthermore, consumer preferences has decreased as people are now much more concentrated on removing non-essential expenses from their budgets as the wider economic situation of most people has been adversely impacted by this outbreak. Over the forecast period, the aforementioned factors are likely to have a negative impact on the hedgehog pathway inhibitors market's revenue trajectory.

Global Hedgehog Pathway Inhibitors Market Scope

The hedgehog pathway inhibitors? market is segmented on the basis of drug, application, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug

• Daurismo
• Erivedge
• Odomzo
• Other

Application

• Basal Cell Carcinoma (BCC)
• Acute Lymphoblastic Leukemia (AML)
• Others

Dosage

• Injection
• Capsule
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Hedgehog Pathway Inhibitors Market Regional Analysis/Insights

The Hedgehog pathway inhibitors? market is analysed and market size insights and trends are provided by country, drug, application, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Hedgehog pathway inhibitors? market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the hedgehog pathway inhibitors? market because of the rising prevalence of basal cell carcinoma and acute myeloid leukaemia in this region. Additionally, growing presence of major key players will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to rising healthcare expenditure and improvements in healthcare infrastructure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Hedgehog Pathway Inhibitors Market Share Analysis

Le paysage concurrentiel du marché des inhibiteurs de la voie Hedgehog fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché des inhibiteurs de la voie Hedgehog.

Certains des principaux acteurs opérant sur le marché des inhibiteurs de la voie Hedgehog sont :

• Pfizer Inc. (États-Unis)
• Novartis SA (Suisse)
• Abbott (États-Unis)
• F. Hoffmann-La Roche SA (Suisse)
• Sanofi (France)
• Sun Pharmaceutical Industries Ltd. (Inde)
• Inhibitor Therapeutics, Inc. (États-Unis)
• MAX BioPharma (États-Unis)
• Mayne Pharma Group Limited (Australie)
• PellePharm Inc. (États-Unis)     

SKU-68097